Lifecore Biomedical, Inc. (LFCR) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

16/25

Growth 5 Margin 2 Expansion 4 Platform 3 Financial 2

latest quarter score

Earnings Reports

16
LifeCore (LFCR) Q2 2026: 200% Demand Surge Locked for 2028, Pipeline Momentum Reshapes Revenue Mix
August 05, 2026
14
LifeCore (LFCR) Q3 2025: Revenue Jumps 26% as CDMO Pipeline and Cost Controls Drive Margin Expansion Path
November 07, 2025
15
LifeCorps (LFCR) Q4 2025: 11 Late-Stage Programs Signal Pipeline Inflection Ahead
August 08, 2025
9
LifeCorps Biomedical (LFCR) Q4 2025: New Programs and Operational Efficiency Drive Transition Year Progress
August 07, 2025
19
LifeCorps (LFCR) Q3 2025: Six New Customers Expand Pipeline as Operational Efficiencies Drive Margin Focus
July 04, 2025
20
LifeCorps Biomedical (LFCR) Q3 2025: $17M Equipment Sale Bolsters Cash as CDMO Revenue Faces Timing Headwinds
April 03, 2025

Browse all companies